| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/15/2008 | WO2008058034A1 Methods of treating dermatological disorders or conditions |
| 05/15/2008 | WO2008058033A2 Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis |
| 05/15/2008 | WO2008058016A2 Ethoid-containing compounds, methods for preparing ethoid-containing compounds, and methods for use |
| 05/15/2008 | WO2008057995A2 Hcv protease inhibitors |
| 05/15/2008 | WO2008057994A2 Pyrrolotriazine kinase inhibitors |
| 05/15/2008 | WO2008057972A1 Methods of synthesizing pharmaceutical salts of a factor xa inhibitor |
| 05/15/2008 | WO2008057948A2 Processes for production of diphenylylazetidin-2-ones and related compounds |
| 05/15/2008 | WO2008057940A1 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| 05/15/2008 | WO2008057938A1 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes |
| 05/15/2008 | WO2008057933A2 Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
| 05/15/2008 | WO2008057930A2 Methods of treating neuropathic pain with retinoic acid receptor agonists |
| 05/15/2008 | WO2008057875A2 Inhibitors of hepatitis c virus |
| 05/15/2008 | WO2008057863A1 Therapeutic combination of a panher/vegfr2 kinase inhibitor and a platinum compound |
| 05/15/2008 | WO2008057859A2 Modulators of glucocorticoid receptor, ap-i and/or nf-kappab activity and use thereof |
| 05/15/2008 | WO2008057857A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF |
| 05/15/2008 | WO2008057856A2 Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| 05/15/2008 | WO2008057775A2 Heterocyclic amide compounds useful as kinase inhibitors |
| 05/15/2008 | WO2008057738A1 Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease |
| 05/15/2008 | WO2008057681A2 Thiophene compounds |
| 05/15/2008 | WO2008057601A2 Organic compounds |
| 05/15/2008 | WO2008057599A2 Methods for the treatment of abeta related disorders and compositions therefor |
| 05/15/2008 | WO2008057562A1 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| 05/15/2008 | WO2008057543A2 Uii-modulating compounds and their use |
| 05/15/2008 | WO2008057534A2 Methods and compositions for organ protection |
| 05/15/2008 | WO2008057516A2 Oxygen delivery composition |
| 05/15/2008 | WO2008057512A2 Imidazopyrazines as protein kinase inhibitors |
| 05/15/2008 | WO2008057511A2 Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof |
| 05/15/2008 | WO2008057503A2 Compositions including triciribine and taxanes and methods of use thereof |
| 05/15/2008 | WO2008057501A2 Immunomodulating compositions and methods of use thereof |
| 05/15/2008 | WO2008057497A2 Small organic molecule regulators of cell proliferation |
| 05/15/2008 | WO2008057469A1 Small organic molecule regulators of cell proliferation |
| 05/15/2008 | WO2008057468A1 Small organic molecule regulators of cell proliferation |
| 05/15/2008 | WO2008057464A2 Compositions and methods for improving the bioavailability of liothyronine |
| 05/15/2008 | WO2008057442A2 Eyelid scrub composition |
| 05/15/2008 | WO2008057423A1 Kits containing benzoyl peroxide pads and a barrier repair composition, and formulations and methods of use therefor |
| 05/15/2008 | WO2008057411A1 Kits containing benzoyl peroxide pads and another acne-treating composition, and formulations and methods of use therefor |
| 05/15/2008 | WO2008057402A2 N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| 05/15/2008 | WO2008057364A1 Method for treating blepharitis |
| 05/15/2008 | WO2008057360A1 Methods of treating an ocular allergy with low dose dexamethasone |
| 05/15/2008 | WO2008057336A2 Heterocyclyl-substituted anti-hypercholesterolemic compounds |
| 05/15/2008 | WO2008057300A2 Trpvi antagonists and uses thereof |
| 05/15/2008 | WO2008057291A2 Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof |
| 05/15/2008 | WO2008057283A2 Use of resolvins for inhibition of bone loss |
| 05/15/2008 | WO2008057254A2 Tricyclic compounds as matrix metalloproteinase inhibitors |
| 05/15/2008 | WO2008057253A2 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
| 05/15/2008 | WO2008057252A2 Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| 05/15/2008 | WO2008057246A2 Method for treating inflammatory disorders |
| 05/15/2008 | WO2008057209A1 Hcv ns3 protease inhibitors |
| 05/15/2008 | WO2008057136A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 05/15/2008 | WO2008057058A1 Oral pharmaceutical compositions |
| 05/15/2008 | WO2008056926A1 Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate |
| 05/15/2008 | WO2008056898A1 Caspase inhibitors based on pyridazinone scaffold |
| 05/15/2008 | WO2008056822A1 Pharmaceutical composition comprising a dihydrobenzofuranyl isoindoline and a lipophilic component |
| 05/15/2008 | WO2008056687A1 Novel spiropiperidine derivative |
| 05/15/2008 | WO2008056657A1 Lyophilized preparation comprising phenanthridine derivative |
| 05/15/2008 | WO2008056654A1 Polymeric derivative of nucleic acid metabolic antagonist |
| 05/15/2008 | WO2008056634A1 Novel hydroxyindole derivative |
| 05/15/2008 | WO2008056596A1 Polymeric derivative of nucleic acid metabolic antagonist |
| 05/15/2008 | WO2008056453A1 Noncarious material and anticarious agent containing rare sugar |
| 05/15/2008 | WO2008056452A1 Utilization of rare sugar for slowing the onset or progress of mobility impairment relating to amyotrophic lateral sclerosis |
| 05/15/2008 | WO2008056433A1 Dendritic polyamidoamine phthalocyanine derivative |
| 05/15/2008 | WO2008056389A1 Drug based on free ozonized oleic acid, process for its preparation, and use of the drug |
| 05/15/2008 | WO2008056388A1 Drug based on ozonized terpenes or terpene-derivatives, processes for producing it and uses thereof |
| 05/15/2008 | WO2008056356A2 Pyrimidine derivatives as posh and posh-ap inhibitors |
| 05/15/2008 | WO2008056335A1 5-hydroxymethyl-oxazolidin-2-one derivatives |
| 05/15/2008 | WO2008056264A2 Novel nucleotide analogues as percursor molecules for antivirals |
| 05/15/2008 | WO2008056259A2 Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 05/15/2008 | WO2008056202A2 Desloratadine crystalline forms mixtures having a low level of residual solvents |
| 05/15/2008 | WO2008056189A1 18, 21-didesoxymacbecin derivatives for the treatment of cancer |
| 05/15/2008 | WO2008056188A2 Novel compounds and methods for their production |
| 05/15/2008 | WO2008056187A1 Imidazolopyrimidines and imidazolotriazine derivatives as inhibitors of poly(adp-ribose) polymerase (parp) |
| 05/15/2008 | WO2008056176A1 Pyrazolopyrimidines as phosphodiesterase inhibitors |
| 05/15/2008 | WO2008056156A1 Salts of dihydroxyanthraquinone carboxylic acids and their therapeutic use |
| 05/15/2008 | WO2008056151A1 Topical formulations |
| 05/15/2008 | WO2008056149A1 Quinazoline derivatives and pharmaceutical compositions containing them |
| 05/15/2008 | WO2008056148A1 Chemical compounds |
| 05/15/2008 | WO2008056120A1 Adenine derivatives as inhibitors of hsp90 for the treatment of cancer |
| 05/15/2008 | WO2008056119A1 N-alkylcarbonyl-d-amino hydroxyalkyl ester compounds and their use |
| 05/15/2008 | WO2008056118A1 N-aryl-hydroxyalkylidene-carboxamide compounds and their use |
| 05/15/2008 | WO2008056059A2 4-azasterol derivatives, methods for the synthesis thereof and use of same as drugs |
| 05/15/2008 | WO2008055997A1 Use of tri-substituted glycerol compounds for the treatment of radiation injuries |
| 05/15/2008 | WO2008055995A2 Methods and compositions for detecting receptor ligand mimetics |
| 05/15/2008 | WO2008055992A1 Composition comprising (-)-δ9-trans-tetrahydrocannabinol |
| 05/15/2008 | WO2008055969A1 Novel triphenylamine derivatives for use as fluorophores in biology, in particular for two-photon microscopy |
| 05/15/2008 | WO2008055966A1 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| 05/15/2008 | WO2008055965A1 Melt-processed imatinib dosage form |
| 05/15/2008 | WO2008055963A1 Novel method for producing organic phosphorus compounds, phosphorus compounds produced using said method, the metal complexes of said compounds, and use of same |
| 05/15/2008 | WO2008055959A1 Novel compounds useful for the treatment of degenerative & inflammatory diseases |
| 05/15/2008 | WO2008055950A1 Novel inhibitors of glutaminyl cyclase |
| 05/15/2008 | WO2008055947A1 Novel inhibitors of glutaminyl cyclase |
| 05/15/2008 | WO2008055945A1 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| 05/15/2008 | WO2008055940A2 Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| 05/15/2008 | WO2008055934A1 Amorphous form of n-{2-fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo [1,5-a]pyrimidin-7-yl]-phenyl-n-methyl-acetamide |
| 05/15/2008 | WO2008055933A1 1,2,3-triazole derivatives as sigma receptor inhibitors |
| 05/15/2008 | WO2008055932A1 1,2,4-triazole derivatives as sigma receptor inhibitors |
| 05/15/2008 | WO2008055924A1 Diagnosis and treatment of t-cell acute lymphoblastic leukemia |
| 05/15/2008 | WO2008055880A1 Process for the sulfinylation of a pyrazole derivative |
| 05/15/2008 | WO2008055879A1 Process for the sulfinylation of a pyrazole derivative |
| 05/15/2008 | WO2008055877A1 Process for the sulfinylation of a pyrazole derivative |
| 05/15/2008 | WO2008055875A1 Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprision thereof and a method for the treatment of a rho-gtpase cell protein-mediated condition |